Matinas BioPharma Holdings Inc (MTNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) has a cash flow conversion efficiency ratio of -0.530x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.60 Million) by net assets ($3.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Matinas BioPharma Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Matinas BioPharma Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Matinas BioPharma Holdings Inc debt and liabilities for a breakdown of total debt and financial obligations.
Matinas BioPharma Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Matinas BioPharma Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reliance Global Group Inc
NASDAQ:RELI
|
-0.077x |
|
Marshalls PLC
LSE:MSLH
|
-0.006x |
|
Caledonia Mining Corporation Plc
LSE:CMCL
|
0.050x |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
0.380x |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
-0.087x |
|
Henderson High Income Trust
LSE:HHI
|
0.029x |
|
Great Atlantic Resources Corp
V:GR
|
0.096x |
|
Aquaporin AS
CO:AQP
|
-0.157x |
Annual Cash Flow Conversion Efficiency for Matinas BioPharma Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Matinas BioPharma Holdings Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Matinas BioPharma Holdings Inc (MTNB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.83 Million | $-7.01 Million | -1.452x | +30.64% |
| 2024-12-31 | $7.59 Million | $-15.88 Million | -2.093x | -163.64% |
| 2023-12-31 | $19.25 Million | $-15.28 Million | -0.794x | -51.82% |
| 2022-12-31 | $36.64 Million | $-19.16 Million | -0.523x | -80.29% |
| 2021-12-31 | $52.49 Million | $-15.22 Million | -0.290x | -6.42% |
| 2020-12-31 | $63.73 Million | $-17.37 Million | -0.273x | +36.08% |
| 2019-12-31 | $33.05 Million | $-14.09 Million | -0.426x | +33.32% |
| 2018-12-31 | $16.14 Million | $-10.32 Million | -0.639x | +40.40% |
| 2017-12-31 | $10.68 Million | $-11.46 Million | -1.073x | -25.36% |
| 2016-12-31 | $7.15 Million | $-6.12 Million | -0.856x | +33.50% |
| 2015-12-31 | $6.07 Million | $-7.81 Million | -1.287x | +63.99% |
| 2014-12-31 | $2.23 Million | $-7.96 Million | -3.573x | -1152.77% |
| 2013-12-31 | $10.47 Million | $-2.99 Million | -0.285x | -69.33% |
| 2012-12-31 | $339.94K | $-57.26K | -0.168x | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more